MedTrace Logo

Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement

NCT07428889 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2026-08-06

No results posted yet for this study

Summary

The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.

Conditions

  • Healthy Adult

Interventions

DIETARY_SUPPLEMENT

Proprietary Nutritional Supplement

1000 mg nicotinamide metabolites and plant extracts, taken orally, daily for 60 days

DIETARY_SUPPLEMENT

Placebo Supplement

1000 mg maltodextrin, taken orally, daily for 60 days

Sponsors & Collaborators

  • Biofortis Clinical Research, Inc.

    collaborator INDUSTRY

  • Nlumn LLC

    collaborator INDUSTRY

  • Shaklee Corporation

    lead INDUSTRY

Principal Investigators

  • Erin Barrett, PhD · Shaklee Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-17
Primary Completion
2026-04-05
Completion
2026-04-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07428889 on ClinicalTrials.gov